All In Biotech

Drug Trial Radar · NCT06556810

IC14 for Treatment of Acute Decompensated Heart Failure

Phase 1b Pilot Study to Evaluate Atibuclimab (IC14) for Treatment of Acute Decompensated Heart Failure

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Oct 17, 2024

Primary completion

Aug 30, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Implicit BioscienceIndustry
Sponsor type
Industry
Collaborators
University of Virginia; Virginia Commonwealth University
First posted
Aug 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug atibuclimab (IC14) works to treat adults hospitalized with acute decompensated heart failure (ADHF). It will also learn about the safety of IC14. The main questions it aims to answer are: Is the drug IC14 safe in patients with ADHF? What are the IC14 drug levels in the bloodstream after treatment with IC14? What is the impact of IC14 treatment on markers of disease in the bloodstream? What is the impact of IC14 treatment on measures of heart failure? There is no placebo arm in this study. Participants will: Take drug IC14 once via an intravenous infusion After the infusion, be visited in the hospital or visit the clinic 5 times for checkups and tests Answer questions about their medical status via a phone call 3 months after the infusion

Conditions

  • Acute Decompensated Heart Failure

Interventions

  • Atibuclimab (IC14)Drug

    Atibuclimab (IC14) is a monoclonal antibody against human cluster of differentiation (CD)14, a key signaling molecule of the innate immune system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of IC14 treatmentTime frame: 0-28 days
  2. Anti-Drug Antibodies following IC14 treatmentTime frame: 0-28 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.